These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 8139872)

  • 1. Respiratory syncytial virus vaccines: can we improve on nature?
    Tristram DA; Welliver RC
    Pediatr Ann; 1993 Dec; 22(12):715-8. PubMed ID: 8139872
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical experience with respiratory syncytial virus vaccines.
    Piedra PA
    Pediatr Infect Dis J; 2003 Feb; 22(2 Suppl):S94-9. PubMed ID: 12671459
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The absence of enhanced disease with wild type respiratory syncytial virus infection occurring after receipt of live, attenuated, respiratory syncytial virus vaccines.
    Wright PF; Karron RA; Belshe RB; Shi JR; Randolph VB; Collins PL; O'Shea AF; Gruber WC; Murphy BR
    Vaccine; 2007 Oct; 25(42):7372-8. PubMed ID: 17868959
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Single-Dose Recombinant Parainfluenza Virus 5-Vectored Vaccine Expressing Respiratory Syncytial Virus (RSV) F or G Protein Protected Cotton Rats and African Green Monkeys from RSV Challenge.
    Wang D; Phan S; DiStefano DJ; Citron MP; Callahan CL; Indrawati L; Dubey SA; Heidecker GJ; Govindarajan D; Liang X; He B; Espeseth AS
    J Virol; 2017 Jun; 91(11):. PubMed ID: 28298602
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Attenuated Human Parainfluenza Virus Type 1 (HPIV1) Expressing the Fusion Glycoprotein of Human Respiratory Syncytial Virus (RSV) as a Bivalent HPIV1/RSV Vaccine.
    Mackow N; Amaro-Carambot E; Liang B; Surman S; Lingemann M; Yang L; Collins PL; Munir S
    J Virol; 2015 Oct; 89(20):10319-32. PubMed ID: 26223633
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunopathology of RSV infection: prospects for developing vaccines without this complication.
    van Drunen Littel-van den Hurk S; Mapletoft JW; Arsic N; Kovacs-Nolan J
    Rev Med Virol; 2007; 17(1):5-34. PubMed ID: 17004293
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Recombinant Respiratory Syncytial Virus Vaccine Candidate Attenuated by a Low-Fusion F Protein Is Immunogenic and Protective against Challenge in Cotton Rats.
    Rostad CA; Stobart CC; Gilbert BE; Pickles RJ; Hotard AL; Meng J; Blanco JCG; Moin SM; Graham BS; Piedra PA; Moore ML
    J Virol; 2016 Aug; 90(16):7508-7518. PubMed ID: 27279612
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current progress on development of respiratory syncytial virus vaccine.
    Chang J
    BMB Rep; 2011 Apr; 44(4):232-7. PubMed ID: 21524347
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Respiratory syncytial virus vaccines: an update on those in the immediate pipeline.
    Esposito S; Di Pietro G
    Future Microbiol; 2016 Oct; 11():1479-1490. PubMed ID: 27750448
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Parainfluenza Virus 5 Expressing Wild-Type or Prefusion Respiratory Syncytial Virus (RSV) Fusion Protein Protects Mice and Cotton Rats from RSV Challenge.
    Phan SI; Zengel JR; Wei H; Li Z; Wang D; He B
    J Virol; 2017 Oct; 91(19):. PubMed ID: 28747496
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vaccines against human respiratory syncytial virus in clinical trials, where are we now?
    Rossey I; Saelens X
    Expert Rev Vaccines; 2019 Oct; 18(10):1053-1067. PubMed ID: 31587585
    [No Abstract]   [Full Text] [Related]  

  • 12. A Respiratory Syncytial Virus Vaccine Vectored by a Stable Chimeric and Replication-Deficient Sendai Virus Protects Mice without Inducing Enhanced Disease.
    Wiegand MA; Gori-Savellini G; Gandolfo C; Papa G; Kaufmann C; Felder E; Ginori A; Disanto MG; Spina D; Cusi MG
    J Virol; 2017 May; 91(10):. PubMed ID: 28250126
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enhanced Neutralizing Antibody Response Induced by Respiratory Syncytial Virus Prefusion F Protein Expressed by a Vaccine Candidate.
    Liang B; Surman S; Amaro-Carambot E; Kabatova B; Mackow N; Lingemann M; Yang L; McLellan JS; Graham BS; Kwong PD; Schaap-Nutt A; Collins PL; Munir S
    J Virol; 2015 Sep; 89(18):9499-510. PubMed ID: 26157122
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Respiratory syncytial virus in infants: is maternal vaccination a realistic strategy?
    Munoz FM
    Curr Opin Infect Dis; 2015 Jun; 28(3):221-4. PubMed ID: 25918956
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhanced pulmonary pathology associated with the use of formalin-inactivated respiratory syncytial virus vaccine in cotton rats is not a unique viral phenomenon.
    Piedra PA; Wyde PR; Castleman WL; Ambrose MW; Jewell AM; Speelman DJ; Hildreth SW
    Vaccine; 1993 Nov; 11(14):1415-23. PubMed ID: 7508665
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The future of respiratory syncytial virus vaccine development.
    Polack FP; Karron RA
    Pediatr Infect Dis J; 2004 Jan; 23(1 Suppl):S65-73. PubMed ID: 14730272
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nucleic acid-based vaccines targeting respiratory syncytial virus: Delivering the goods.
    Smith TRF; Schultheis K; Broderick KE
    Hum Vaccin Immunother; 2017 Nov; 13(11):2626-2629. PubMed ID: 28881156
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Strategic priorities for respiratory syncytial virus (RSV) vaccine development.
    Anderson LJ; Dormitzer PR; Nokes DJ; Rappuoli R; Roca A; Graham BS
    Vaccine; 2013 Apr; 31 Suppl 2(Suppl 2):B209-15. PubMed ID: 23598484
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunization of macaques with formalin-inactivated respiratory syncytial virus (RSV) induces interleukin-13-associated hypersensitivity to subsequent RSV infection.
    De Swart RL; Kuiken T; Timmerman HH; van Amerongen G; Van Den Hoogen BG; Vos HW; Neijens HJ; Andeweg AC; Osterhaus AD
    J Virol; 2002 Nov; 76(22):11561-9. PubMed ID: 12388717
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of a recombinant live attenuated respiratory syncytial virus vaccine candidate that is highly attenuated in infants.
    Karron RA; Wright PF; Belshe RB; Thumar B; Casey R; Newman F; Polack FP; Randolph VB; Deatly A; Hackell J; Gruber W; Murphy BR; Collins PL
    J Infect Dis; 2005 Apr; 191(7):1093-104. PubMed ID: 15747245
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.